ELL2 Activators comprise a series of chemical compounds that indirectly bolster the functional performance of ELL2 through distinct signaling pathways. Forskolin and IBMX operate through the cAMP signaling pathway, with Forskolin activating adenylate cyclase and IBMX inhibiting phosphodiesterases, collectively resulting in heightened cAMP levels which can enhance the phosphorylation state of transcription co-factors associating with ELL2, thus augmenting its transcription elongation capabilities. Phorbol 12-myristate 13-acetate (PMA) and Sphingosine-1-phosphate further contribute by activating PKC and lipid signaling pathways respectively, which then may lead to phosphorylation of interacting proteins or changes in thechromatin structure that bolster ELL2's role in transcriptional elongation. EGCG adds to this enhancement by inhibiting kinases that target transcription factor coactivators, potentially increasing ELL2's efficiency in the transcription elongation process.
Moreover, compounds such as 5-Azacytidine and Trichostatin A, which inhibit DNA methyltransferases and histone deacetylases respectively, contribute to a chromatin landscape that is more conducive to transcription, thereby facilitating ELL2's elongation activity. BIX-01294, by inhibiting histone methylation, and (S)-CR8, by inhibiting CDKs, particularly CDK9, can also promote an environment favoring transcriptional elongation. JQ1's displacement of competitive BET proteins from chromatin may allow for ELL2 to engage more effectively with the transcription machinery, while SR-48692's modulation of neurotensin signaling could upregulate transcriptional elongation processes that ELL2 is a part of. Lastly, C646's targeting of HAT activity can lead to altered acetylation patterns, potentially enhancing ELL2's interaction with the transcriptional apparatus and facilitating its role in elongation. These ELL2 Activators, through their targeted influence on various cellular pathways, ensure the promotion of ELL2-mediated transcription without the need for direct stimulation or overexpression.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels in cells. The elevation in cAMP can enhance the activity of ELL2 by promoting the phosphorylation of transcription factors that synergize with ELL2 in the elongation phase of transcription. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which increases intracellular levels of cAMP by preventing its breakdown. This would enhance ELL2 activity indirectly by stabilizing the transcription complex it associates with through cAMP-dependent protein kinase (PKA) signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is an activator of protein kinase C (PKC) which can lead to the phosphorylation of proteins that interact with ELL2, potentially enhancing its transcription elongation activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor known to affect multiple pathways, including those regulating transcription. It may enhance ELL2 activity by inhibiting kinases that would otherwise phosphorylate and inhibit transcription factors or coactivators working with ELL2. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate is a lipid signaling molecule that can activate signaling pathways leading to alterations in chromatin structure, potentially facilitating ELL2's role in transcription elongation by making the DNA template more accessible. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is an inhibitor of DNA methyltransferases, which can lead to a more open chromatin state. This could indirectly enhance ELL2 activity by increasing the accessibility of DNA for the transcription machinery. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor, which causes acetylation of histones, leading to a more open chromatin configuration. This could enhance the action of ELL2 by facilitating the transcriptional elongation process. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 (free base) | sc-202651 | 5 mg | $151.00 | 4 | |
BIX-01294 is an inhibitor of G9a histone methyltransferase, leading to reduced methylation of histone H3. The resulting changes in chromatin structure could enhance ELL2-mediated transcription elongation by improving the binding of ELL2 to the transcription complex. | ||||||
SR 48692 | 146362-70-1 | sc-363290 sc-363290A sc-363290B sc-363290C sc-363290D | 5 mg 25 mg 100 mg 500 mg 1 g | $159.00 $605.00 $2374.00 $10710.00 $21410.00 | 2 | |
SR-48692 is an antagonist of neurotensin receptor 1, which can modulate various intracellular signaling pathways. It could enhance ELL2 activity by influencing pathways that upregulate transcriptional elongation processes ELL2 is involved in. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a selective p300/CBP histone acetyltransferase (HAT) inhibitor. By modulating acetylation levels, it can influence the transcriptional activity and potentially enhance ELL2 function by modifying the acetylation state of proteins associated with transcription elongation. | ||||||